Linking blood inflammation markers and chest CT findings in adults with stable bronchiectasis who frequently flare
Official title: Correlation of Inflammatory Markers and Radiological Findings in Stable Bronchiectasis Patients With Exacerbation Phenotype
Run by Sohag University · NCT07495982 · Data updated 2026-11-12
This project will test whether blood inflammatory markers match chest CT findings in adults with stable non-CF bronchiectasis who have frequent exacerbations.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Sohag University Academic / other |
| Locations | 1 site (Sohag) |
| Status | Recruiting |
| Started | November 1, 2025 |
| Main results expected | November 1, 2026 |
| Study ends | November 1, 2026 |
| Registry record updated | March 27, 2026 |
| Trial ID | NCT07495982 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with HRCT-confirmed non-cystic fibrosis bronchiectasis, particularly those with a history of two or more exacerbations per year and who are clinically stable at sampling, are ideal candidates.
✕Probably not a fit
People with cystic fibrosis-related bronchiectasis, active pulmonary tuberculosis, advanced hepatic or renal failure, current immunosuppressive therapy, or those unwilling to participate are excluded and unlikely to benefit from this project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational project will enroll adults (≥18) with non-cystic fibrosis bronchiectasis confirmed by high-resolution CT and characterize their exacerbation phenotype. Participants who are clinically stable will have blood inflammatory markers measured and their recent HRCT scans reviewed. Investigators will look for correlations between biomarker levels, specific radiological features, and the history of frequent exacerbations (≥2 per year). All activities are observational and conducted without experimental treatments at the Faculty of Medicine, Sohag University.
Why it matters
Potential benefit: If successful, the findings could help identify simple blood markers that signal higher risk of exacerbations and guide closer monitoring or more personalized care.
How similar studies have gone: Previous observational studies have reported some links between inflammatory markers and imaging severity in bronchiectasis, but results have been inconsistent and this approach is not yet validated for routine care.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * adult patients (≥18 years) with non-cystic fibrosis bronchiectasis confirmed by High Resolution Computed Tomography (HRCT). Exclusion Criteria: * Patients with cystic fibrosis-related bronchiectasis. * Patients with active pulmonary tuberculosis. * Patients with chronic debilitating diseases e.g. advanced hepatic or renal diseases. * Patients with primary autoimmune or malignancy requiring immunosuppressive therapy at the time of the marker measurement. * Patients refusing participation.
Where it's running
-
Faculty of medicine
Sohag, Egypt Recruiting
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.